Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HCR040 in Acute Respiratory Distress Syndrome
NCT04289194Phase 2Completed
- Sponsor
- Histocell
- Start
- Dec 2019
- Primary completion
- Aug 2021
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of HCR040 in acute respiratory distress syndrome (ARDS) (3 arms), sponsored by Histocell. Primary endpoint: Number of adverse events at 1 year. Started Dec 2019; status: completed.
02
Drugs
HCR040
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04289194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04289194.